Avenzo Therapeutics
Oncology Therapeutics
$595.9Mtotal raised · 3 rounds on record
2open roles
$60Mlatest round · Series B · Sep 2025 · 13 mo ago
4backers · NEA, OrbiMed
Overview
Avenzo Therapeutics is a clinical-stage biotechnology company that develops next-generation targeted oncology therapies. It was co-founded in 2022 and hires directors in biologics process development, accounting, financial planning and data management. The company is headquartered in San Diego, California, United States.
Funding and backers
Total raised
$595.9M
3 rounds on record
Latest round
$60M
Series B · Sep 2025 · 13 mo ago
Team
201-500
employees, estimated range
Hiring now
2
open roles
Backers
4
NEA, OrbiMed
The money's age
Due for its next round
13 months since the last round · hiring slowed
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 2
Board appointment Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors · avenzotx.com
Nov 17, 2025
New executive Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer · avenzotx.com
Sep 19, 2025
Raised a round Series B $60M
Aug 28, 2025
Certified Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific… · avenzotx.com
May 20, 2025
Certified Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Se… · businesswire.com
Mar 26, 2024
Raised a round Venture round $150M · Pulse 2.0
Sep 29, 2022
Board appointment Michael Rome, Director · SEC Form D
Sep 14, 2022
Raised a round Venture round $385.9M · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Sep 2025 | $60M | — | avenzotx.com |
| Venture round | Mar 2024 | $150M | — | Pulse 2.0 |
| Venture round | Sep 2022 | $385.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Avenzo Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Paolo TombesiExecutive OfficerSEC Form D
Mohammad HirmandExecutive OfficerSEC Form D
Scott LipmanExecutive OfficerSEC Form D
Athena CountouriotisExecutive Officer, DirectorSEC Form D
Brian SunExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Eisbach Bio is a clinical-stage biotechnology company developing next-generation cancer therapies with its proprietary ALLOS platform.
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
BrainChild Bio is a kids-first, clinical-stage biotechnology company harnessing the power of CAR-T cell technology for tumors in the…
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor targeting the…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…
Jobs
$290k – $328k per year · Equity · Hybrid · Full-Time · 12+ years exp · PhD · San Diego
Interpretability
Apply
$223k – $233k per year · Equity · Hybrid · Full-Time · 8+ years exp · Master's Degree
Cell Culture
Chromatography
GMP
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$194k
Typical range
$150k – $328k
Open positions
4
4
Jobs
Senior
25%
Staff
50%
Architect
25%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $328k | $328k |
| Staff | 2 | $152k | $150k – $154k |
| Architect | 1 | $233k | $233k |
Highest paying role
Senior/Executive Director, Clin Pharmacology
$328k
Normalized to USD per year
Growth
Hiring Momentum
24/100
Hiring freeze
Open positions
4
0 opened / 0 closed in 30 days
Median time-to-fill
48 days
faster than 28% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
33% ▼
HR
22% ▼
Leadership
11% ▼
Administrative
11% ▲
Industrial Engineering
11% ▲
Biotech
11% ▲
People
Paolo Tombesi
Executive Officer
Mohammad Hirmand
Executive Officer
Scott Lipman
Executive Officer
Athena Countouriotis
Executive Officer, Director
Brian Sun
Executive Officer
Carl Gordon
Director
Garry Nicholson
Director
Patrick Machado
Director
Judith Li
Director
Simeon George
Director
Jakob Dupont M.D. M.A.
Director
Michael Rome
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Avenzo Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
7
Postings analysed
3
Stack modernity
55/100
Cloud & platforms
GCP
Practices & domains
CDISC
GMP
Good Clinical Practice
Interpretability
Cell Culture
Chromatography
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SR OneVia a fund
Sofinnova InvestmentsVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
NEAVia a fund
672 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Avenzo Therapeutics Expands Leadership Team
SAN DIEGO, September 28, 2026--Avenzo Therapeutics Expands Leadership Team
Read more
Report
Avenzo Therapeutics Expands Leadership Team
.avia-section.av-8p9y1p-024d036820a305bbc343caa4caaa016a{ margin-top:60px; margin-bottom:0px; } #top .av-special-heading.av-max6k29w-f6ad8e01643625fe8b8fce4ce0193da4{ padding-bottom:10px; } body .av-special-heading.av-max6k29w-f6ad8e01643625fe8b8fce4ce019
Read more
Report
Rallybio CFO Transition Amid Pending Avenzo Therapeutics Merger
Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.
Read more
Report
Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium
.avia-section.av-8p9y1p-024d036820a305bbc343caa4caaa016a{ margin-top:60px; margin-bottom:0px; } #top .av-special-heading.av-max6k29w-f6ad8e01643625fe8b8fce4ce0193da4{ padding-bottom:10px; } body .av-special-heading.av-max6k29w-f6ad8e01643625fe8b8fce4ce019
Read more
Report
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors
.avia-section.av-8p9y1p-024d036820a305bbc343caa4caaa016a{ margin-top:60px; margin-bottom:0px; } #top .av-special-heading.av-max6k29w-f6ad8e01643625fe8b8fce4ce0193da4{ padding-bottom:10px; } body .av-special-heading.av-max6k29w-f6ad8e01643625fe8b8fce4ce019
Read more
Report
Avenzo Therapeutics to Participate in the Upcoming Wells Fargo 21st Annual Healthcare Conference
Read more
Report
Avenzo Therapeutics Announces Appointment of Connie Wedel as Chief Human Resources Officer
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
San Diego
San Diego
United States
HQ
3 open roles 7 posted in 90 days 200-500 est. staff $211k Avg Salary
hires for Finance, HR, Biotech